Mitral Regurgitation:
|
|
- Quentin Johns
- 6 years ago
- Views:
Transcription
1 Mitral Regurgitation: Diagnosis and Treatment 2018 Annual Chattanooga Cardiology Symposium 10 February, 2018 Allen E. Atchley, MD
2 Disclosures None Objectives: 1. Understand functional vs. degenerative MR 2. Understand MR severity grading 3. Understand indications for surgery/intervention
3 Outline Epidemiology/Anatomy Regurgitation Classification Myxomatous Degeneration MR Severity Grading Guidelines for Management MitraClip Procedural Animation Case Presentation
4 Epidemiology Mitral regurgitation prevalence (any) 70% by TTE Significant (Moderate-Severe) 2-3% of general population 7-8 million U.S. adults million world wide
5 atomy/leaflets.jpg Online access 10/2017. Mitral valve anatomy
6 Pathophysiology Chronic MR = Volume Insidious: Structural s PRECEDE symptoms Symptoms: Heart Failure - Exertional SOB - Activity Intolerance - Fatigue - Edema - Orthopnea - Cough Palpitations (Atrial Fibrillation)
7 MR Etiology Degenerative MR - Primary/Organic - Structural abnormality of any part of the mitral apparatus Functional MR - Secondary MR - LV dysfunction/enlargement
8 MR Etiology
9 Carpentier Classification 58/ Access online 10/2017
10 Myxomatous Schematic of normal Degeneration: mitral valve histology. Fibroelastic Deficiency (FED) VEC: Valvular Endothelial Cells VIC: Valvular Interstitial Cells Francesca N. Delling, and Ramachandran S. Vasan Circulation. 2014;129: Copyright American Heart Association, Inc. All rights reserved.
11 Myxomatous Degeneration: Spectrum of Disease _ehq22201&req=4. Access online 10/2017.
12 Myxomatous Degeneration: Progression of Disease Proposed temporal spectrum of mitral valve (MV) prolapse (MVP) progression with potential interventions/nonsurgical therapies depending on progression stage (bottom). Francesca N. Delling, and Ramachandran S. Vasan Circulation. 2014;129:
13
14 MR Severity- Echo
15 MR Severity- Echo
16 Follow-up: ASE Guidelines Mild MR - Echo: q3-5 years Moderate MR - Echo: annual Severe MR - Referral (TEE +/- intervention) * Echo for any murmur or symptoms
17 Treatment Medical therapy - BP mgmt. (ARB/ACE-I) * MR is dynamic - diuretics CAD/Ischemia (IIIB) - revascularization?
18 Treatment: ARB? Animal study with ARB = protective antifibrotic/anti-inflammatory effect. EMT- endothelial to mesenchymal transition.
19 Clinical Outcomes: Med Rx From: Prevalence and Outcomes of Unoperated Patients With Severe Symptomatic Mitral Regurgitation and Heart Failure: Comprehensive Analysis to Determine the Potential Role of MitraClip for This Unmet Need 1095 patients with Severe MR and HF FMR 74%, DMR 21%, Other 5% 53% Medical Therapy and 47% Surgery Journal of the American College of Cardiology Jan 2014, 63 (2) ; DOI: /j.jacc
20 Treatment Surgical - Valve replacement - Mechanical (warfarin) - Bioprosthetic (90%, warfarin 3-6mo. then ASA) - Valve repair - Ring +/- resection - Alfieri stitch * DMR- prohibitive surgical risk - Transcatheter repair (MitraClip)
21 ACC Guidelines: Surgery LV Dysfxn: EF < 60% ESd > 4cm EF < 30% or ESd > 5.5 cm = Med Rx IIb- Left Atrial Enlargement
22 109 Pts with Asymptomatic MR: Quantified by cmri
23 Early Surgery: Asymptomatic Severe MR Duk-Hyun Kang et al. Circulation. 2009;119:
24
25 Case Case 85 y/o with progressive HF symptoms (exertional shortness of breath and fatigue) 3-4/6 murmur of MR on exam
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41 Conculsions Degenerative MR- primary valve disease Functional MR- secondary (LV dysfxn, MI, etc.) Chronic MR is insidious - structural s typically precede HF signs/symptoms Medical Therapy- limited role in treatment Early Surgical Intervention! - severe MR +/- LVEF < 60% or LVSd > 4.0cm High risk patients with DMR-? MitraClip
42 References Nishimura RA, Otto CM, Bonow RO, Carabello BA, et al AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease, Journal of the American College of Cardiology (2014, doi; /j.jacc ) Francesca N. Delling, and Ramachandran S. Vasan. Circulation. 2014; 129: Goel SS, Navkaranbir B, Aggarwal B, et al. Prevalence and Outcomes of Unoperated Patients With Severe Symptomatic Mitral Regurgitation and Heart Failure. JACC. 2014; 63 (2): Thavendiranathan P, Phelan D, Collier P, et al. Quantitative Assessment of Mitral Regurgitation. JACC Cardiovascular Imaging. 2012; 5 (11): Myerson SG, d Arcy J, Christiansen JP, et al. Determination of Clinical Outcome in Mitral Regurgitation With Cardiovascular Magnetic Resonance Quantification. Circulation. 2016;133:
43 Questions?
Mitral Regurgitation
Mitral Regurgitation Focus on Percutaneous Repair Steven J. Yakubov, MD FACC FSCAI System Chief, Structural Heart Diseaese, OhioHealth John H. McConnell Chair of Advanced Structural Heart Disease Medical
More informationPercutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat
Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Innovative Procedures, Devices & State of the Art Care for Arrhythmias, Heart Failure & Structural Heart Disease October 8-10,
More informationPrimary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017
Disclosures: GE stock, Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017 Athena Poppas, MD FACC Past ACC Scientific Sessions Chair, ACC Board
More information2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease
2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease Patrick T. O Gara, MD BWH Heart and Vascular Center Professor of Medicine, Harvard Medical School Disclosures NHLBI CTSN Co-chair
More informationMinimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F.
Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F. Attizzani, MD UH Harrington Heart and Vascular Institute Interventional Cardiologist/Structural
More informationReshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid
Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid Patient records 76 y.o. male Hypertension. Dyslipidemia. OPLD. Smoked in the past. Diabetes
More informationCases of mitral valve causing mitral regurgitation: the MV prolapse spectrum CASE
Cases of mitral valve causing mitral regurgitation: the MV prolapse spectrum Judy Hung, MD Cardiology Division Massachusetts General Hospital Boston, MA CASE Mr. M; 50 Year male presents to internist for
More informationPERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL
PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL DISCLOSURES I WILL BE DISCUSSING OFF-LABEL USAGE OF DEVICES RELATED TO TMVR OBJECTIVES
More informationWorldwide rheumatic fever is the most common cause of valve disease. In industrialized areas, valvular disease of old age predominates
Michael Sumners DO Epidemiology Worldwide rheumatic fever is the most common cause of valve disease In industrialized areas, valvular disease of old age predominates Calcific aortic stenosis Functional
More informationDisclosure Statement of Financial Interest Saibal Kar, MD, FACC
MitraClip Therapy Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Program Director, Interventional Cardiology Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA
More informationOutline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines
Advances in Percutaneous Mitral Valve Repair and Replacement Scott M Lilly MD PhD, Interventional Cardiology The Ohio State University Contemporary Multidisciplinary Cardiovascular Conference Orlando,
More informationThe Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD
The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New
More informationAsymptomatic Valvular Disease:
Asymptomatic Valvular Disease: Can Echocardiography Help You Decide When to Intervene? Neil J. Weissman, MD MedStar Health Research Inst at MedStar Washington Hospital Center & Professor of Medicine Georgetown
More informationΕπιδιόπθωζη μιηποειδικήρ ζςζκεςήρ ζε ππόπηωζη ή πήξη γλωσίνων. Βαζίλειορ Σασπεκίδηρ Επιμεληηήρ Β Καπδιολογίαρ Γ.Ν. Παπαγεωπγίος
Επιδιόπθωζη μιηποειδικήρ ζςζκεςήρ ζε ππόπηωζη ή πήξη γλωσίνων Βαζίλειορ Σασπεκίδηρ Επιμεληηήρ Β Καπδιολογίαρ Γ.Ν. Παπαγεωπγίος MV anatomy Otto C. NEJM 2001 Leaflets anatomy 2% of population Etiology Terminology
More informationHeart Valve disease: MR. AS tough patient When to echo, When to refer, What s new
Heart Valve disease: MR. AS tough patient When to echo, When to refer, What s new B. Sonnenberg UAH Cardiology CME Day 5 May 2015 Disclosures Speaker s or Advisory Boards: none Research grants: none (co-investigator
More informationMITRAL VALVE DISEASE- ASSESSMENT AND MANAGEMENT. Irene Frantzis P year, SGUL Sheba Medical Center
MITRAL VALVE DISEASE- ASSESSMENT AND MANAGEMENT Irene Frantzis P year, SGUL Sheba Medical Center MITRAL VALVE DISEASE Mitral Valve Regurgitation Mitral Valve Stenosis Mitral Valve Prolapse MITRAL REGURGITATION
More informationDegenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention
Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention John N. Hamaty D.O. FACC, FACOI November 17 th 2017 I have no financial disclosures Primary Mitral
More informationOverview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan
Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan Degenerative MR is not Functional MR 2o - Functional MR : Ventricular Problem!!
More informationChronic Primary Mitral Regurgitation
Chronic Primary Mitral Regurgitation The Case For Early Surgical Intervention William K. Freeman, MD, FACC, FASE DISCLOSURES Relevant Financial Relationship(s) None Off Label Usage None Watchful Waiting......
More informationMITRAL REGURGITATION REFERRAL TOOLKIT
1. Patient Case Summary Worksheets Use these checklists to help collect all necessary patient information. Initial echocardiogram MR symptoms and related conditions Patient conditions that may impact therapy
More informationValvular Heart Disease Mitral Stenosis
Valvular Heart Disease Mitral Stenosis A 75 year old woman with loud first heart sound and mid-diastolic murmur Chronic dyspnea Class 2/4 Fatigue Recent orthopnea/pnd Nocturnal palpitation Pedal edema
More informationPercutaneous Mitral Valve Repair
Percutaneous Mitral Valve Repair MitraClip: Procedure, Data, Patient Selection Chad Rammohan, MD FACC Director, Cardiac Cath Lab El Camino Hospital Mountain View, California Mitral Regurgitation MitraClip
More informationTREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC
TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC NATURAL HISTORY OF MITRAL REGURGITATION Abdallah El Sabbagh et al. JIMG 2018;11:628-643 TREATMENT OPTIONS SURGERY REPAIR REPLACEMENT PERCUTANEOUS INTERVENTIONS
More informationTranscatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott. Chairperson: M. Haude Panellists: A. Al Nooryani, M.
Transcatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott Chairperson: M. Haude Panellists: A. Al Nooryani, M. Al Otaiby Session objectives To learn about the clinical patient profile for
More informationManagement of TR in Patients Undergoing Mitral Interventions
Management of TR in Patients Undergoing Mitral Interventions Stephen H. Little, MD John S. Dunn Chair in Cardiovascular Research and Education, Associate professor, Weill Cornell Medicine shlittle@houstonmethodist.org
More informationUnderstanding the guidelines for Interventions in MR. Ali AlMasood
Understanding the guidelines for Interventions in MR Ali AlMasood Mitral regurgitation The most diverse from all acquired valve diseases About 50% of patients with an LVEF 35 percent had moderate to severe
More information8/31/2016. Mitraclip in Matthew Johnson, MD
Mitraclip in 2016 Matthew Johnson, MD 1 Abnormal Valve Function Valve Stenosis Obstruction to valve flow during that phase of the cardiac cycle when the valve is normally open. Hemodynamic hallmark - pressure
More informationAn Overview of Mainstream Structural Heart Therapies: TAVR/MitraClip/Watchman
An Overview of Mainstream Structural Heart Therapies: TAVR/MitraClip/Watchman Yakima Valley Medical Conference Moses Mathur MD MSc March 2018 Outline CC : 85 yo M w/ Shortness of breath TTE : Cardiomyopathy
More informationSecondary MR joint with the mitral academy. What is new in our understanding of this disease? Luc Pierard University Hospital, Liège
Secondary MR joint with the mitral academy What is new in our understanding of this disease? Luc Pierard University Hospital, Liège Faculty disclosure Luc Pierard I have no financial relationships to disclose.
More informationThe production of murmurs is due to 3 main factors:
Heart murmurs The production of murmurs is due to 3 main factors: high blood flow rate through normal or abnormal orifices forward flow through a narrowed or irregular orifice into a dilated vessel or
More informationThe production of murmurs is due to 3 main factors:
Heart murmurs The production of murmurs is due to 3 main factors: high blood flow rate through normal or abnormal orifices forward flow through a narrowed or irregular orifice into a dilated vessel or
More informationThe Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream
The Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org
More informationValvular Guidelines: The Past, the Present, the Future
Valvular Guidelines: The Past, the Present, the Future Robert O. Bonow, MD, MS Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern Memorial Hospital Editor-in-Chief,
More informationLes valvulopathies en sourdine: la valve mitrale Quoi faire devant une régurgitation mitrale sévère asymptomatique de type dégénérative?
Réunion d automne de la SSC à Lucerne le 24.11.2011 Incertitudes dans le travail cardiologique quotidien Les valvulopathies en sourdine: la valve mitrale Quoi faire devant une régurgitation mitrale sévère
More informationWatchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg
Watchman and Structural update..the next frontier Ari Chanda, MD Cardiology Associates of Fredericksburg Different Left Atrial Appendage (LAA) morphologies Watchman (the device) Fabric Anchors Device structure
More informationValvular Heart Disease. Dr. HANAN ALBACKR
Valvular Heart Disease Dr. HANAN ALBACKR Valvular Heart Disease Format for this lecture IMPORTANT CLINICAL INFO know for boards, tests and clinical practice Spectrum of VHD Aortic Valve Mitral Valve Tricuspid
More informationI (312) Mitral Regurgitation What Should You Know?
Mitral Regurgitation What Should You Know? Table of Contents What is Mitral Regurgitation? 3 What are the Symptoms? 4 What are the risks? 5 Who Gets Mitral Regurgitation? 6 Diagnosing Mitral Regurgitation
More informationQuantitation of Aortic Regurgitation ASCeXAM / ReASCE Review Course
Quantitation of Aortic Regurgitation 2017 ASCeXAM / ReASCE Review Course David Adams, ACS, RCS, RDCS, FASE Duke University Medical Center May 1, 2017 Disclosures None 1 Exam based on: Zoghbi et al. JASE
More informationOrganic mitral regurgitation
The best in heart valve disease Organic mitral regurgitation Ewa Szymczyk Department of Cardiology Medical University of Lodz, Poland I have nothing to declare Organic mitral regurgitation leaflet abnormality
More informationHistorical perspective R1 黃維立
Degenerative mitral valve disease refers to a spectrum of conditions in which morphologic changes in the connective tissue of the mitral valve cause structural lesions that prevent normal function of the
More informationAcute Valve Regurgitation Catherine M. Otto, MD J. Ward Kennedy-Hamilton Endowed Chair in Cardiology University of Washington, Seattle
Acute Valve Regurgitation Catherine M. Otto, MD J. Ward Kennedy-Hamilton Endowed Chair in Cardiology University of Washington, Seattle No conflicts of interest Acute Aortic Regurgitation Causes aortic
More informationCase Report. Percutaneous Mitral Repair with MitraClip as an Adjunct Therapy of Heart Failure. Introduction. Case Report. Keywords
Percutaneous Mitral Repair with MitraClip as an Adjunct Therapy of Heart Failure Petherson Susano Grativvol, 1,2 Katiuska Massucatti Grativvol, 1,2 Alberto de Paula Nogueira Jr., 1,2 João Eduardo Tinoco
More informationValvular Heart Disease Transcatheter Valve Therapies. October 2016 Brian Whisenant MD
Valvular Heart Disease Transcatheter Valve Therapies October 2016 Brian Whisenant MD Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationValvular Heart Disease: Recognition and Management in the Outpatient Setting
Valvular Heart Disease: Recognition and Management in the Outpatient Setting Ian S. Harris UCSF Division of Cardiology Case 1: 80 year old man with a history of hypertension, complaining of exertional
More informationMitral Valve Disease, When to Intervene
Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages
More information2/4/2019. Nursing Perspective of TAVR. Disclosure. Learning Outcomes
Nursing Perspective of TAVR Tara Whitmire, DNP, APRN-NP, NP-C, CHFN Nebraska Methodist Hospital Cardiothoracic Surgery Nurse Practitioner Danelle Homeyer, RN Methodist Physicians Clinic Director, Structural
More informationExpanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?
Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,
More informationEVALUATION OF CHRONIC MITRAL REGURGITATION: ASSESSING MECHANISMS AND QUANTIFYING SEVERITY 2018 STRUCTURAL HEART DISEASE CONFERENCE June 1, 2018
1 EVALUATION OF CHRONIC MITRAL REGURGITATION: ASSESSING MECHANISMS AND QUANTIFYING SEVERITY 2018 STRUCTURAL HEART DISEASE CONFERENCE June 1, 2018 David A. Orsinelli, MD, FACC, FASE Professor, Internal
More informationWhat echo measurements are key prior to MitraClip?
APHP CHU Bichat - Claude Bernard What echo measurements are key prior to MitraClip? Eric Brochet,MD Cardiology Department Hopital Bichat Paris France No disclosure Conflict of interest Case 69 y.o man
More informationStatus Of The MitraClip: Trials (EVEREST II & COAPT) & FDA
Status Of The MitraClip: Trials (EVEREST II & COAPT) & FDA Ted Feldman, M.D., FSCAI FACC FESC Evanston Hospital SCAI Fall Fellows Course Las Vegas, Nevada December 8 11 th, 2013 Ted Feldman MD, FACC, FESC,
More informationLoad and Function - Valvular Heart Disease. Tom Marwick, Cardiovascular Imaging Cleveland Clinic
Load and Function - Valvular Heart Disease Tom Marwick, Cardiovascular Imaging Cleveland Clinic Indications for surgery in common valve lesions Risks Operative mortality Failed repair - to MVR Operative
More informationSecondary Mitral Regurgitation: When Should We Intervene?
/19/17 Secondary Mitral Regurgitation: When Should We Intervene? Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern Memorial Hospital
More informationWhat Degree of MR Deserves Surgical or Transcatheter Intervention, and How Should It Be Assessed?
What Degree of MR Deserves Surgical or Transcatheter Intervention, and How Should It Be Assessed? Robert J. Siegel, M.D., FACC Nov. 14-15, 2017, Beverly Hills Director, Cardiac Non-Invasive Laboratory
More informationLong-Term Outcome of Patients With Aortic Regurgitation: Medical Management and Surgical Indications
24th Annual Advances in Heart Disease 16 December 2007 Long-Term Outcome of Patients With Aortic Regurgitation: Medical Management and Surgical Indications Melvin D. Cheitlin, M.D. Emeritus Professor of
More informationNora Goldschlager, M.D. SFGH Division of Cardiology UCSF
CLASSIFICATION OF HEART FAILURE Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF DISCLOSURES: NONE CLASSIFICATION C OF HEART FAILURE NYHA I IV New paradigm Stage A: Pts at high risk of developing
More informationOutcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S.
ACC 2015 LBCT Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S. A report from the STS/ACC TVT Registry Paul Sorajja, MD, Saibal Kar, MD, Amanda Stebbins,
More informationTranscatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT
Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT and Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac
More informationValve Analysis and Pathoanatomy: THE MITRAL VALVE
: THE MITRAL VALVE Marc R. Moon, M.D. John M. Shoenberg Chair in CV Disease Chief, Cardiac Surgery Washington University School of Medicine, St. Louis, MO Secretary, American Association for Thoracic Surgery
More informationCardiac Valve/Structural Therapies
Property of Dr. Chad Rammohan Cardiac Valve/Structural Therapies Chad Rammohan, MD FACC Medical Director, El Camino Hospital Cardiac Catheterization Lab Director, Interventional and Structural Cardiology,
More informationPrognostic Impact of FMR
Secondary Mitral Valve Regurgitation in Heart Failure, Age 60 Years From Medical Therapy to Surgical Repair to Transcatheter Intervention The Interventionalist s View Samin K Sharma, MD, FACC, FSCAI Director
More informationTSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD
TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)
More informationMedical Treatment for AS. Disclosures. Valvular Heart Disease. Aortic Stenosis. Severe Symptomatic AS Survival. Disease Progression in Aortic Stenosis
Disclosures Valvular Heart Disease Akshay Desai, MD Brigham and Women s Hospital Harvard Medical School Consultant: Novartis Pharmaceuticals Boston Scientific Intel, Inc. Relypsa, Inc. Research Grants:
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationTitle of image and video article Sub-Acute Leaflet Thrombosis: A Reversible Cause of Aortic Stenosis
Page 1 of 5 Title of image and video article Sub-Acute Leaflet Thrombosis: A Reversible Cause of Aortic Stenosis Authors Athina Chasapi, Adam Hobbs, Theodore Velissaris & Benoy N Shah. Wessex Cardiac &
More informationDobutamine Stress testing In Low Flow, Low EF, Low Gradient Aortic Stenosis Case Studies
Dobutamine Stress testing In Low Flow, Low EF, Low Gradient Aortic Stenosis Case Studies Mitral Regurgitation The New ASE Guidelines: Role of 2D/3D and CMR William A. Zoghbi MD, FASE, MACC Professor and
More informationCLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ;
CLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ; Επιµορφωτικά Σεµινάρια Ειδικευοµένων Καρδιολογίας 7 Απριλίου 2012 M Chrissoheris MD FACC THV Department HYGEIA Hospital Degenerative MR (DMR) Usually refers to an anatomic
More informationΣεμινάρια Ομάδων Εργασίας 2017 Ανεπάρκεια μιτροειδούς μυξωματώδους αιτιολογίας
Σεμινάρια Ομάδων Εργασίας 2017 Ανεπάρκεια μιτροειδούς μυξωματώδους αιτιολογίας Μυτάς Δημήτρης MD, PhD Επιμ Α ΕΣΥ Σισμανόγλειο Γενικό Νοσοκομείο Αττικής Δηλώνω υπεύθυνα ότι η παρούσα ομιλία δεν επιχορηγείται
More informationUpdate on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center
Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock
More informationEndocarditis and Its Complications: The Role of Echocardiography
Endocarditis and Its Complications: The Role of Echocardiography Pravin Patil, MD FACC FASE Associate Professor of Medicine Director, Cardiovascular Disease Training Program Lewis Katz School of Medicine
More informationQuality Outcomes Mitral Valve Repair
Quality Outcomes Mitral Valve Repair Moving Beyond Reoperation Rakesh M. Suri, D.Phil. Professor of Surgery 2015 MFMER 3431548-1 Disclosure Mayo Clinic Division of Cardiovascular Surgery Research funding
More informationChapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine
Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine Mitral regurgitation, regurgitant flow between the
More informationAortic regurgitation. Physiopathology. Dr Pilar Tornos Hospital Vall d Hebron. Barcelona Eurovalve 2014
Aortic regurgitation. Physiopathology Dr Pilar Tornos Hospital Vall d Hebron. Barcelona Eurovalve 2014 Faculty disclosure Pilar Tornos I have no financial relationships to disclose. Acute AR Etiology:
More informationValvular Heart Disease
Valvular Heart Disease B K Singh, MD, FACC Disclosures: None 1 CARDIAC CYCLE S2 S2=A2P2 S1=M1T1 S4 S1 S3 2 JVP Carotid S1 Slitting of S2 S3 S4 Ejection click Opening snap Dynamic Auscultation What is the
More informationAortic Valvular Stenosis
Aortic Valvular Stenosis How to Assess the Four Variables for Management Low Flow / Low Gradient / Normal EF / Low EF Patrick T. O Gara, MD, MACC Brigham and Women s Hospital Harvard Medical School No
More informationEcho in Asymptomatic Mitral and Aortic Regurgitation
2017 ASE Florida Orlando, FL October 9, 2017 10:40 11:00 PM 20 min Grand Harbor Ballroom South Echo in Asymptomatic Mitral and Aortic Regurgitation Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology
More informationIndex. B B-type natriuretic peptide (BNP), 76
Index A ACCESS-EU registry, 158 159 Acute kidney injury (AKI), 76, 88 Annular enlargement, RV, 177 178 Annuloplasty chordal cutting, 113 complete ring, 99 etiology-specific ring, 100 evolution, 98 flexible
More informationAortic Stenosis: UPDATE Anjan Sinha, MD Krannert Institute of Cardiology
Aortic Stenosis: UPDATE 2010 Anjan Sinha, MD Krannert Institute of Cardiology None Disclosures 67-Year-Old Male Dyspnea and angina Class III heart failure No PND or orthopnea 3/6 late peak SEM Diminished
More informationTranscatheter Mitral & Tricuspid Therapies. Bernard J. Zovighian Corporate Vice President
Transcatheter Mitral & Tricuspid Therapies Bernard J. Zovighian Corporate Vice President We Will Lead and Transform Treatment for Patients with Mitral and Tricuspid Diseases Mitral and Tricuspid Diseases
More informationTranscatheter Valve Therapies Update
Providence Heart and Vascular Institute Transcatheter Valve Therapies Update Where In The H*@# Is All This Going??? Robert Hodson MD Medical Director, Providence Valve Center October 24, 2015 DISCLOSURES
More informationWhen is it too late to perform transcatheter mitral valve repair? Alec Vahanian, FESC,FRCP(Edin.) Bichat hospital University Paris VII
When is it too late to perform transcatheter mitral valve repair? Alec Vahanian, FESC,FRCP(Edin.) Bichat hospital University Paris VII I, (Alec Vahanian) DO have a financial interest/arrangement or affiliation
More informationMitral Valve Prolapse and Sudden Death. JF Avierinos Hôpital Timone Marseille January 27th, 2017
Mitral Valve Prolapse and Sudden Death JF Avierinos Hôpital Timone Marseille January 27th, 2017 Mitral Valve Prolapse Between Benign and Malignant the Long Story of Figure an Ongoing Controversy of a Pathologic
More informationRegurgitant Lesions. Bicol Hospital, Legazpi City, Philippines July Gregg S. Pressman MD, FACC, FASE Einstein Medical Center Philadelphia, USA
Regurgitant Lesions Bicol Hospital, Legazpi City, Philippines July 2016 Gregg S. Pressman MD, FACC, FASE Einstein Medical Center Philadelphia, USA Aortic Insufficiency Valve anatomy and function LVOT and
More informationHeart Failure. Dr. William Vosik. January, 2012
Heart Failure Dr. William Vosik January, 2012 Questions for clinicians to ask Is this heart failure? What is the underlying cause? What are the associated disease processes? Which evidence-based treatment
More informationEulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain
Eulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain Device Landscape 2010 PERCUTANEOUS TECHNIQUES Percutaneous indirect annuloplasty Percutaneous direct annuloplasty Edge to Edge ( E-Valve ) Non
More informationMitral Valve prolapse: What s new? Which indications of early surgery? Input of new 2017 ESC/EACTS guidelines. Christophe Tribouilloy Amiens, France
Mitral Valve prolapse: What s new? Which indications of early surgery? Input of new 2017 ESC/EACTS guidelines Christophe Tribouilloy Amiens, France I have no financial relationships to disclose related
More informationGDMT for percutaneous mitral valve repair
GDMT for percutaneous mitral valve repair Ted Feldman, M.D., MSCAI FACC FESC Evanston Hospital The 11th Annual Innovations & Trends in Cardiovascular Care New Brunswick, NJ October 18 th 2014 Ted Feldman
More informationTranscatheter Mitral Innovations, Part II. Michael Mack, M.D. Baylor Scott & White Health
Transcatheter Mitral Innovations, Part II Michael Mack, M.D. Baylor Scott & White Health Conflict of Interest Disclosure Co-PI of the COAPT Trial of MitraClip sponsored by Abbott Vascular Uncompensated
More informationMitral Valve Disease. James Hermiller, MD, FACC, FSCAI St Vincent Heart Center Indianapolis, IN
Mitral Valve Disease James Hermiller, MD, FACC, FSCAI St Vincent Heart Center Indianapolis, IN Disclosures Affiliation/Financial Relationship Consulting Fees/Honoraria Speaker Bureau Company Abbott, BSC,
More informationStress Testing in Valvular Disease
2017 ASE Florida Orlando, FL October 10, 2017 2:40 2:50 PM 10 min Grand Harbor Ballroom South Stress Testing in Valvular Disease Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate
More informationEjection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.
Valvular Heart Disease Etiology General Principles Cellular and molecular mechanism of valve damage Structural pathology Functional pathology - stenosis/regurgitation Loading conditions - pressure/volume
More informationOutcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease
Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease TIRONE E. DAVID, MD ; SEMIN THORAC CARDIOVASC SURG 19:116-120c 2007 ELSEVIER INC. PRESENTED BY INTERN 許士盟 Mitral valve
More informationSusan P. D Anna MSN, APRN BC February 14, 2019
Is there Equal Opportunity in Heart Failure?? Susan P. D Anna MSN, APRN BC February 14, 2019 Disclosures: I have no financial disclosures. I am not an expert on this topic, but see a lot of women with
More informationBurden of Mitral Regurgitation (MR) in the US Why is This Important?
Secondary (Functional) Mitral Regurgitation as a Target for Heart Failure Therapy William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCP Professor of Medicine, Physiology, and Cell Biology Chair of Excellence
More informationUse of MitraClip Beyond Everest Criteria
Use of MitraClip Beyond Everest Criteria Takashi Matsumoto, MD Sendai Kousei Hospital Sendai, Japan No Disclosure of Financial Interest Introduction The efficacy and safety of the MitraClip therapy was
More informationWelcome 17 Michigan TAVR Participating Hospitals!
Welcome 17 Michigan TAVR Participating Hospitals! 1 MICHIGAN TAVR BRIEF OVERVIEW HOW AND WHY PRE-TAVR IMAGING EVALUATION AND THE TVT Michael Grossman, MD Co-Director, BMC2 Coordinating Center Why Michigan
More informationDISCLOSURE. Mitral ViV: why? Mitral Valve- in- Valve: Procedural Image Guidance with TEE, a Must Have or Nice to Have? UW Medicine NONE.
Mitral Valve- in- Valve: Procedural Image Guidance with TEE, a Must Have or Nice to Have? G. Burkhard Mackensen, MD, PhD, FASE Professor & Chief, Division of Cardiothoracic Anesthesia, Department of Anesthesiology
More informationAortic Regurgitation & Aorta Evaluation
VALVULAR HEART DISEASE Regurgitation Valvular Lessions 2017 Aortic Regurgitation & Aorta Evaluation Jorge Eduardo Cossío-Aranda MD, FACC Chairman of Outpatient Care Department Instituto Nacional de Cardiología
More informationI have financial relationships to disclose Honoraria from: Edwards
I have financial relationships to disclose Honoraria from: Edwards Mitral Valve Annuloplasty in Ischemic Mitral regurgitation Jean François Avierinos Hôpital Timone Marseille August 28, 2012 Ischemic MR
More informationEjection across stenotic aortic valve requires a systolic pressure gradient between the LV and aorta. This places a pressure load on the LV.
Valvular Heart Disease General Principles Etiology Cellular and molecular mechanism of valve damage Structural pathology Functional pathology - stenosis/regurgitation Loading conditions - pressure/volume
More information